Mechanical Stretch Induces Monocyte Chemoattractant Activity via an NF-κB-Dependent Monocyte Chemoattractant Protein-1-Mediated Pathway in Human Mesangial Cells
Open Access
- 1 March 2005
- journal article
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 16 (3) , 688-696
- https://doi.org/10.1681/asn.2004030251
Abstract
Hemodynamic abnormalities are important in the pathogenesis of the glomerular damage in diabetes. Glomerular macrophage infiltration driven by the chemokine monocyte chemoattractant protein-1 (MCP-1) is an early event in diabetic nephropathy. The thiazolidinedione rosiglitazone ameliorates albumin excretion rate in diabetic patients with microalbuminuria and has anti-inflammatory properties, raising the possibility of a relationship between its renoprotective and anti-inflammatory activity. Investigated was whether mesangial cell stretching, mimicking in vitro glomerular capillary hypertension, enhances MCP-1 expression and monocyte chemoattractant activity. The effect of the combination of stretch with high glucose on MCP-1 production was studied and, finally, the effect of rosiglitazone on these processes was assessed. Stretching of human mesangial cells significantly enhanced their monocyte chemoattractant activity. This effect was mediated by MCP-1 as it was paralleled by a significant rise in both MCP-1 mRNA and protein levels and was completely abolished by MCP-1 blockade. Combined exposure to both stretch and high glucose further increased MCP-1 production. Stretch activated the IκB-NF-κB pathway, and NF-κB inhibition, with the use of the specific inhibitor SN50, completely abolished stretch-induced MCP-1, indicating that stretch-induced MCP-1 was NF-κB dependent. The addition of rosiglitazone significantly diminished stretch-induced NF-κB activation, MCP-1 production, and monocyte chemotaxis. In conclusion, stretching of mesangial cells stimulates their monocyte chemoattractant activity via an NF-κB-mediated, MCP-1-dependent pathway, and this effect is prevented by rosiglitazone.Keywords
This publication has 43 references indexed in Scilit:
- PPARγ ligands induce prostaglandin production in vascular smooth muscle cells: indomethacin acts as a peroxisome proliferator‐activated receptor‐γ antagonistThe FASEB Journal, 2003
- Suppression of experimental crescentic glomerulonephritis by peroxisome proliferator-activated receptor (PPAR)? activatorsClinical and Experimental Nephrology, 2003
- Nonrequirement of Continuous Stimulation with MCP-1 for Cell Migration and Determination of Directional Migration by Initial Stimulation with ChemokineExperimental Cell Research, 2002
- Pharmacokinetics of Rosiglitazone in Patients with End-Stage Renal DiseaseJournal of International Medical Research, 2002
- Uni‐axial cyclic stretch induces the activation of transcription factor nuclear factor κB in human fibroblast cellsThe FASEB Journal, 2002
- Pressure-induced expression of monocyte chemoattractant protein-1 through activation of MAP kinaseKidney International, 2001
- Peroxisome proliferator-activated receptor-γ agonist troglitazone protects against nondiabetic glomerulosclerosis in ratsKidney International, 2001
- Expression and Function of Peroxisome Proliferator–Activated Receptor-γ in Mesangial CellsHypertension, 2001
- Proinflammatory gene expression and macrophage recruitment in the rat remnant kidneyKidney International, 2000
- Monocyte Chemoattractant Protein-1 Expression in Aortic Tissues of Hypertensive RatsHypertension, 1997